Human Gene MIR34A (ENST00000385130.1) from GENCODE V47lift37
|
|
Sequence and Links to Tools and Databases
|
|
Primer design for this transcript
|
|
Comparative Toxicogenomics Database (CTD)
|
|
RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
|
|
Orthologous Genes in Other Species
|
|
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
Mouse | Rat | Zebrafish | D. melanogaster | C. elegans | S. cerevisiae |
No ortholog | No ortholog | No ortholog | No ortholog | No ortholog | No ortholog |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
|
| |
|
|
Descriptions from all associated GenBank mRNAs
|
|
EF570048 - Homo sapiens microRNA 34a (MIRN34A) precursor RNA, complete sequence. EF592573 - Homo sapiens microRNA-34a primary transcript, complete sequence. EF609116 - Homo sapiens precursor microRNA mir-34a, complete sequence. CS266366 - Sequence 58 from Patent WO2005118806. DL076528 - METHODS AND COMPOSITIONS INVOLVING MicroRNA. DM004178 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. FU261115 - MICRORNA EXPRESSION ABNORMALITIES IN PANCREATIC ENDOCRINE AND ACINAR TUMORS. FU763617 - MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS. FV525818 - Nucleic acid controling mast cell degranulation. FW421520 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. FW504782 - COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER. HI508133 - Sequence 2 from Patent EP2152722. HV304516 - JP 2009531018-A/83: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER. HV305014 - JP 2009531019-A/83: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HW102015 - JP 2013500034-A/142: Use of microRNA for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells. HW119223 - JP 2013046612-A/83: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HW367391 - JP 2012228254-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HW411784 - JP 2014000079-A/58: METHODS AND COMPOSITIONS INVOLVING MicroRNA. HW505133 - JP 2014502606-A/35: MELANOMA TREATMENTS. HW589552 - JP 2013121348-A/83: MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS. HW674130 - JP 2014217381-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ067072 - JP 2014012020-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ408233 - JP 2015528002-A/830: CHIRAL CONTROL. HZ413356 - JP 2014060993-A/83: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HZ427496 - JP 2014217384-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ428299 - JP 2014217385-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ429102 - JP 2014217386-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ429905 - JP 2014217387-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ501567 - JP 2016025853-A/83: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HZ769162 - JP 2014223080-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. JA058556 - Sequence 58 from Patent EP2298893. JA059359 - Sequence 58 from Patent EP2298894. JA073682 - Sequence 58 from Patent EP2281887. JA104819 - Sequence 58 from Patent EP2302051. JA106159 - Sequence 58 from Patent EP2302052. JA106962 - Sequence 58 from Patent EP2302053. JA107765 - Sequence 58 from Patent EP2302054. JA108568 - Sequence 58 from Patent EP2302055. JA109371 - Sequence 58 from Patent EP2302056. JA191887 - Sequence 58 from Patent EP2290066. JA192786 - Sequence 58 from Patent EP2290067. JA193685 - Sequence 58 from Patent EP2290068. JA194584 - Sequence 58 from Patent EP2290069. JA195483 - Sequence 58 from Patent EP2290070. JA196382 - Sequence 58 from Patent EP2290071. JA197281 - Sequence 58 from Patent EP2290072. JA198180 - Sequence 58 from Patent EP2290073. JA199079 - Sequence 58 from Patent EP2290074. JA199978 - Sequence 58 from Patent EP2290075. JA200877 - Sequence 58 from Patent EP2290076. JA217999 - Sequence 58 from Patent EP2281888. JA226150 - Sequence 58 from Patent EP2292755. JA229005 - Sequence 58 from Patent EP2292756. JA257276 - Sequence 58 from Patent EP2284265. JA278556 - Sequence 58 from Patent EP2281886. JA284442 - Sequence 58 from Patent EP2281889. JA292495 - Sequence 58 from Patent EP2287303. JA317681 - Sequence 58 from Patent EP2314688. JA374740 - Sequence 58 from Patent EP2322616. JA525933 - Sequence 83 from Patent EP2369011. JA526440 - Sequence 83 from Patent EP2369012. JA526947 - Sequence 83 from Patent EP2369013. JA535876 - Sequence 83 from Patent EP2371971. JA787881 - Sequence 83 from Patent EP2479285. JA788379 - Sequence 83 from Patent EP2479286. JA810713 - Sequence 83 from Patent EP2468890. JA811211 - Sequence 83 from Patent EP2468891. JA811709 - Sequence 83 from Patent EP2468893. JA812207 - Sequence 83 from Patent EP2468894. JA812705 - Sequence 83 from Patent EP2468895. JA813203 - Sequence 83 from Patent EP2468896. JA813701 - Sequence 83 from Patent EP2468897. JA814199 - Sequence 83 from Patent EP2468898. JA814697 - Sequence 83 from Patent EP2468899. JA816940 - Sequence 83 from Patent EP2468892. JA825752 - Sequence 83 from Patent EP2471956. JA826250 - Sequence 83 from Patent EP2471958. JB024537 - Sequence 83 from Patent EP2505668. JB025035 - Sequence 83 from Patent EP2505669. JB079422 - Sequence 83 from Patent EP2487252. JB079920 - Sequence 83 from Patent EP2487253. JB080418 - Sequence 83 from Patent EP2487254. JB080916 - Sequence 83 from Patent EP2487255. JB081414 - Sequence 83 from Patent EP2487256. JB081912 - Sequence 83 from Patent EP2487257. JB082410 - Sequence 83 from Patent EP2487258. JB082908 - Sequence 83 from Patent EP2487259. JB083406 - Sequence 83 from Patent EP2487260. JB083904 - Sequence 83 from Patent EP2487261. JB084402 - Sequence 83 from Patent EP2487262. JB084900 - Sequence 83 from Patent EP2487263. JB087578 - Sequence 83 from Patent EP2502630. JB147782 - Sequence 83 from Patent EP2484782. JB148280 - Sequence 83 from Patent EP2484783. JB153005 - Sequence 83 from Patent EP2514433. JB153503 - Sequence 83 from Patent EP2514434. JB622092 - Sequence 83 from Patent EP2586454. JB622590 - Sequence 83 from Patent EP2586455. JC001653 - Sequence 83 from Patent EP2591794. JC037592 - Sequence 120 from Patent EP2643479. JC221583 - Sequence 58 from Patent EP2471923. JC268149 - Sequence 58 from Patent EP2471924. JC340457 - Sequence 58 from Patent EP2471922. JC469703 - Sequence 58 from Patent EP2471921. JC572000 - Sequence 14 from Patent EP2759595. JC990492 - Sequence 58 from Patent EP2808390. LF132449 - JP 2016506923-A/14: Composition comprising an encapsulated antagomir. LF714595 - JP 2016165292-A/58: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. LF856529 - JP 2015142597-A/58: METHODS AND COMPOSITIONS INVOLVING MicroRNA. LG051567 - KR 1020150036642-A/833: CHIRAL CONTROL. LG162313 - KR 1020160018451-A/14: Composition comprising an encapsulated antagomir. LP010721 - Sequence 26 from Patent EP2977463. LZ228144 - JP 2017524341-A/2: HYBRID TRNA/PRE-MIRNA MOLECULES AND METHODS OF USE. MS810731 - Sequence 1 from Patent EP3142707. CS266560 - Sequence 252 from Patent WO2005118806. DL076722 - METHODS AND COMPOSITIONS INVOLVING MicroRNA. DM004372 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. FW421714 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HW367585 - JP 2012228254-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HW411978 - JP 2014000079-A/252: METHODS AND COMPOSITIONS INVOLVING MicroRNA. HW674324 - JP 2014217381-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ067266 - JP 2014012020-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ427690 - JP 2014217384-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ428493 - JP 2014217385-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ429296 - JP 2014217386-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ430099 - JP 2014217387-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. HZ769356 - JP 2014223080-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. JA058750 - Sequence 252 from Patent EP2298893. JA059553 - Sequence 252 from Patent EP2298894. JA073876 - Sequence 252 from Patent EP2281887. JA105013 - Sequence 252 from Patent EP2302051. JA106353 - Sequence 252 from Patent EP2302052. JA107156 - Sequence 252 from Patent EP2302053. JA107959 - Sequence 252 from Patent EP2302054. JA108762 - Sequence 252 from Patent EP2302055. JA109565 - Sequence 252 from Patent EP2302056. JA192081 - Sequence 252 from Patent EP2290066. JA192980 - Sequence 252 from Patent EP2290067. JA193879 - Sequence 252 from Patent EP2290068. JA194778 - Sequence 252 from Patent EP2290069. JA195677 - Sequence 252 from Patent EP2290070. JA196576 - Sequence 252 from Patent EP2290071. JA197475 - Sequence 252 from Patent EP2290072. JA198374 - Sequence 252 from Patent EP2290073. JA199273 - Sequence 252 from Patent EP2290074. JA200172 - Sequence 252 from Patent EP2290075. JA201071 - Sequence 252 from Patent EP2290076. JA218193 - Sequence 252 from Patent EP2281888. JA226344 - Sequence 252 from Patent EP2292755. JA229199 - Sequence 252 from Patent EP2292756. JA257470 - Sequence 252 from Patent EP2284265. JA278750 - Sequence 252 from Patent EP2281886. JA284636 - Sequence 252 from Patent EP2281889. JA292689 - Sequence 252 from Patent EP2287303. JA317875 - Sequence 252 from Patent EP2314688. JA374934 - Sequence 252 from Patent EP2322616. JC221777 - Sequence 252 from Patent EP2471923. JC268343 - Sequence 252 from Patent EP2471924. JC340651 - Sequence 252 from Patent EP2471922. JC469897 - Sequence 252 from Patent EP2471921. JC990686 - Sequence 252 from Patent EP2808390. LF714789 - JP 2016165292-A/252: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES. LF856723 - JP 2015142597-A/252: METHODS AND COMPOSITIONS INVOLVING MicroRNA. FW364245 - Oligonucleotides for modulating target RNA activity. FW504815 - COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER. HI508166 - Sequence 35 from Patent EP2152722. HI560876 - Sequence 91 from Patent EP2190992. HI965152 - Sequence 437 from Patent WO2010139812. HI965788 - Sequence 108 from Patent WO2010139811. HI966654 - Sequence 108 from Patent WO2010139810. HV593977 - JP 2010538653-A/91: MIRNA EXPRESSION IN HUMAN PERIPHERAL BLOOD MICROVESICLES AND USES THEREOF. HV595154 - JP 2010539959-A/535: Micromirs. HW101963 - JP 2013500034-A/90: Use of microRNA for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells. HW505500 - JP 2014502606-A/402: MELANOMA TREATMENTS. HW913253 - JP 2015504307-A/13: METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS. HZ074021 - JP 2013535982-A/112: Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer. HZ083046 - JP 2015513906-A/403: Stem Cell Microparticles. HZ157711 - JP 2015130862-A/535: Micromirs. HZ186558 - JP 2015146814-A/307: Oligonucleotides for modulating target RNA activity. HZ436827 - JP 2015529450-A/403: Stem Cell Microparticles. HZ466305 - JP 2015531594-A/8: METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS. HZ480234 - JP 2015535430-A/740: TERMINALLY MODIFIED RNA. HZ790165 - JP 2016504050-A/1910: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. JA287408 - Sequence 90 from Patent WO2011015720. JA401190 - Sequence 437 from Patent WO2011080318. JA402168 - Sequence 437 from Patent WO2011080315. JA403175 - Sequence 437 from Patent WO2011080316. JA405806 - Sequence 437 from Patent EP2336353. JA426978 - Sequence 311 from Patent WO2011072177. JA429332 - Sequence 437 from Patent WO2011095623. JA660623 - Sequence 77 from Patent WO2011131354. JB022201 - Sequence 43 from Patent WO2013026685. JB022754 - Sequence 8 from Patent WO2013026684. JB074834 - Sequence 94 from Patent WO2012168448. JB620062 - Sequence 42 from Patent WO2013063544. JB620196 - Sequence 176 from Patent WO2013063544. JB624271 - Sequence 91 from Patent EP2610342. JB778634 - Sequence 13 from Patent WO2013078283. JB982240 - Sequence 18 from Patent WO2013190091. JC172031 - Sequence 403 from Patent WO2013150303. JC244447 - Sequence 67 from Patent WO2012020308. JC512897 - Sequence 3150 from Patent WO2014113089. JC572031 - Sequence 45 from Patent EP2759595. JC572842 - Sequence 403 from Patent WO2014125276. JC582530 - Sequence 403 from Patent WO2014125277. JE954226 - Sequence 403 from Patent WO2015052526. JE955979 - Sequence 403 from Patent WO2015052527. JE978632 - Sequence 77 from Patent EP2865765. LF132480 - JP 2016506923-A/45: Composition comprising an encapsulated antagomir. LF137731 - JP 2016507550-A/403: Method of Producing Microparticles. LF160053 - JP 2016513950-A/119: Oligomers with improved off-target profile. LF162696 - JP 2016513095-A/403: Stem Cell Microparticles and miRNA. LF953448 - JP 2016534103-A/403: Stem Cell Microparticles and miRNA. LG005793 - KR 1020150004822-A/403: STEM CELL MICROPARTICLES. LG053489 - KR 1020150059168-A/403: STEM CELL MICROPARTICLES. LG162344 - KR 1020160018451-A/45: Composition comprising an encapsulated antagomir. LG240728 - KR 1020160035087-A/403: STEM CELL MICROPARTICLES AND MIRNA. LP726414 - Sequence 108 from Patent EP2883966. LP818684 - Sequence 108 from Patent EP3296406. LP938626 - Sequence 108 from Patent EP3184651. LQ070485 - Sequence 809 from Patent EP2964234. LQ417667 - Sequence 3 from Patent WO2016125163. LQ441087 - Sequence 94 from Patent EP3029157. LQ731203 - Sequence 39 from Patent EP3325624. LV470813 - JP 2016534036-A/403: Stem Cell Microparticles and miRNA. LY405219 - KR 1020160117535-A/524: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. LZ233915 - JP 2017184756-A/307: Oligonucleotides for modulating target RNA activity. MA260458 - JP 2017505623-A/524: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. MS673205 - Sequence 8 from Patent EP3135774. MS833386 - Sequence 91 from Patent EP3112464. MS834291 - Sequence 437 from Patent EP3112479. MS901570 - Sequence 43 from Patent EP3156505. LQ417666 - Sequence 2 from Patent WO2016125163. AY194151 - Homo sapiens microRNA miR-34, complete sequence. CQ873674 - Sequence 93 from Patent WO2004076622. CS548417 - Sequence 1447 from Patent EP1777301. DD413511 - Regulation of Mammalian Cells. FV524273 - Nucleic acid controling mast cell degranulation. FW312159 - DETECTING NUCLEIC ACIDS. FZ436961 - JP 2011501966-A/8: PROCESS FOR MONITORING COLORECTAL CANCER. HI463857 - Sequence 2 from Patent EP2124967. HV335759 - JP 2011093892-A/2: Tumor proliferation suppressor comprising tumor suppressive micro RNA. HV534432 - WO 2011111715-A/948: Nucleic acid for controlling cell cycle. JC265631 - Sequence 1 from Patent WO2013017542. JC334246 - Sequence 164 from Patent EP2487240. JE869360 - Sequence 1 from Patent WO2015131115. LF636227 - JP 2016519076-A/1: COMBINATION CANCER TREATMENTS UTILIZING MICRORNA AND EGFR-TKI INHIBITORS. LF838608 - JP 2016530232-A/3: Biomarkers of miR-34 Activity. LG134384 - KR 1020150131312-A/1: COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS. LP637005 - Sequence 55 from Patent EP2848702. LQ069373 - Sequence 1 from Patent WO2015153757. LY409556 - KR 1020160122850-A/1: SORAFENIB-MICRORNA COMBINATION THERAPY FOR LIVER CANCER. MA264538 - JP 2017507955-A/1: SORAFENIB-MICRORNA COMBINATION THERAPY FOR LIVER CANCER. AJ550399 - Homo sapiens microRNA mir-34. CS166329 - Sequence 40 from Patent WO2005078096. CS265299 - Sequence 41 from Patent EP1627925. CS444354 - Sequence 41 from Patent WO2006108473. DI488453 - KR 1020140147919-A/1: Biomaker miR-451 for distinguishing non-alcoholic steatohepatitis. DI488460 - KR 1020140147920-A/1: Biomaker miR-34a for distinguishing non-alcoholic steatohepatitis. DI488467 - KR 1020140147921-A/1: Biomaker miR-494-3p for distinguishing non-alcoholic steatohepatitis. DJ003842 - Method for predicting or identifying target mRNAs of functional RNAs and use thereof. DJ027121 - Method for predicting or identifying target mRNAs of functional RNAs and use thereof. DL231871 - Method for the determination of cellular transcriptional regulation. FU261388 - MICRORNA EXPRESSION ABNORMALITIES IN PANCREATIC ENDOCRINE AND ACINAR TUMORS. FU763890 - MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS. FW362676 - MICRORNA EXPRESSION SIGNATURE FOR PREDICTING SURVIVAL AND METASTASES IN HEPATOCELLULAR CARCINOMA. FW364244 - Oligonucleotides for modulating target RNA activity. FW504781 - COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER. FZ414384 - WO 2011007815-A/274: A method for screening a food which promotes production of milk having immunoregulating effect. HH981318 - Sequence 78 from Patent EP1723162. HI377383 - Sequence 10 from Patent EP2087135. HI508132 - Sequence 1 from Patent EP2152722. HI528954 - Sequence 34 from Patent EP2142659. HI539279 - Sequence 103 from Patent EP2160477. HI560875 - Sequence 90 from Patent EP2190992. HI929402 - Sequence 9 from Patent EP2258863. HI965153 - Sequence 438 from Patent WO2010139812. HI966097 - Sequence 417 from Patent WO2010139811. HI966963 - Sequence 417 from Patent WO2010139810. HV304789 - JP 2009531018-A/356: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER. HV305287 - JP 2009531019-A/356: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HV321528 - JP 2011072229-A/35: Diagnosis and therapeutic choice of hypopharyngeal cancer using micro RNA as biomarker. HV511981 - JP 2011520454-A/96: Methods for Assessing Colorectal Cancer and Compositions for use therein. HV540977 - WO 2011125469-A/21: A recombinant vaccinia virus regulated by miRNA and use thereof. HV543935 - JP 2011217617-A/46: Method for testing fibrosis of chronic liver diseases using miRNAs. HV582960 - JP 2010527616-A/101: Micro-RNA Scaffolds and Non-Naturally Occurring Micro-RNAS. HV593976 - JP 2010538653-A/90: MIRNA EXPRESSION IN HUMAN PERIPHERAL BLOOD MICROVESICLES AND USES THEREOF. HV595153 - JP 2010539959-A/534: Micromirs. HV753278 - JP 2012509865-A/1: Compositions and methods for treating retrovirus infections. HV753797 - JP 2012509675-A/35: COMPOSITIONS AND METHODS FOR DETECTING SMALL RNAS, AND USES THEREOF. HV821912 - JP 2011140513-A/274: An Immunostimulating pharmaceutical composition, and a method for producing the immunostimulating pharmaceutical composition. HV954026 - JP 2012518421-A/938: METHODS OF DETECTING LUNG CANCER. HV956208 - JP 2012519484-A/5: LIVE ATTENUATED INFLUENZA VIRUS VACCINES COMPRISING MICRORNA RESPONSE ELEMENTS. HW060376 - JP 2012527478-A/40: Identification of MicroRNAs Involved in Post-Myocardial Infarction Remodeling and Heart Failure. HW101911 - JP 2013500034-A/38: Use of microRNA for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells. HW119496 - JP 2013046612-A/356: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HW248829 - JP 2013514372-A/28: MICRO-RNA REGULATION IN ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY. HW505322 - JP 2014502606-A/224: MELANOMA TREATMENTS. HW589825 - JP 2013121348-A/356: MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS. HW669843 - JP 2013537538-A/574: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS. HW913406 - JP 2015504307-A/166: METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS. HZ074020 - JP 2013535982-A/111: Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer. HZ082744 - JP 2015513906-A/101: Stem Cell Microparticles. HZ157710 - JP 2015130862-A/534: Micromirs. HZ186557 - JP 2015146814-A/306: Oligonucleotides for modulating target RNA activity. HZ376551 - WO 2015133521-A/3: New RNA sequence exhibiting anti-tumor effect. HZ413629 - JP 2014060993-A/356: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HZ432168 - JP 2014207909-A/101: Micro-RNA Scaffolds and Non-Naturally Occurring Micro-RNAS. HZ436525 - JP 2015529450-A/101: Stem Cell Microparticles. HZ466303 - JP 2015531594-A/6: METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS. HZ480235 - JP 2015535430-A/741: TERMINALLY MODIFIED RNA. HZ501840 - JP 2016025853-A/356: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS. HZ790166 - JP 2016504050-A/1911: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. JA287356 - Sequence 38 from Patent WO2011015720. JA401191 - Sequence 438 from Patent WO2011080318. JA402169 - Sequence 438 from Patent WO2011080315. JA403176 - Sequence 438 from Patent WO2011080316. JA405807 - Sequence 438 from Patent EP2336353. JA427139 - Sequence 472 from Patent WO2011072177. JA429333 - Sequence 438 from Patent WO2011095623. JA483461 - Sequence 96 from Patent EP2283161. JA526206 - Sequence 356 from Patent EP2369011. JA526713 - Sequence 356 from Patent EP2369012. JA527220 - Sequence 356 from Patent EP2369013. JA536149 - Sequence 356 from Patent EP2371971. JA660765 - Sequence 219 from Patent WO2011131354. JA667970 - Sequence 49 from Patent WO2011139911. JA682630 - Sequence 98 from Patent WO2011149354. JA715156 - Sequence 938 from Patent EP2401406. JA729546 - Sequence 5 from Patent EP2403527. JA781917 - Sequence 28 from Patent EP2513307. JA788154 - Sequence 356 from Patent EP2479285. JA788652 - Sequence 356 from Patent EP2479286. JA792094 - Sequence 143 from Patent WO2012089753. JA810986 - Sequence 356 from Patent EP2468890. JA811484 - Sequence 356 from Patent EP2468891. JA811982 - Sequence 356 from Patent EP2468893. JA812480 - Sequence 356 from Patent EP2468894. JA812978 - Sequence 356 from Patent EP2468895. JA813476 - Sequence 356 from Patent EP2468896. JA813974 - Sequence 356 from Patent EP2468897. JA814472 - Sequence 356 from Patent EP2468898. JA814970 - Sequence 356 from Patent EP2468899. JA817213 - Sequence 356 from Patent EP2468892. JA826025 - Sequence 356 from Patent EP2471956. JA826523 - Sequence 356 from Patent EP2471958. JB024810 - Sequence 356 from Patent EP2505668. JB025308 - Sequence 356 from Patent EP2505669. JB029510 - Sequence 34 from Patent EP2481805. JB029570 - Sequence 34 from Patent EP2481806. JB079695 - Sequence 356 from Patent EP2487252. JB080193 - Sequence 356 from Patent EP2487253. JB080691 - Sequence 356 from Patent EP2487254. JB081189 - Sequence 356 from Patent EP2487255. JB081687 - Sequence 356 from Patent EP2487256. JB082185 - Sequence 356 from Patent EP2487257. JB082683 - Sequence 356 from Patent EP2487258. JB083181 - Sequence 356 from Patent EP2487259. JB083679 - Sequence 356 from Patent EP2487260. JB084177 - Sequence 356 from Patent EP2487261. JB084675 - Sequence 356 from Patent EP2487262. JB085173 - Sequence 356 from Patent EP2487263. JB087851 - Sequence 356 from Patent EP2502630. JB148055 - Sequence 356 from Patent EP2484782. JB148553 - Sequence 356 from Patent EP2484783. JB149199 - Sequence 274 from Patent EP2455486. JB153278 - Sequence 356 from Patent EP2514433. JB153776 - Sequence 356 from Patent EP2514434. JB233508 - Sequence 40 from Patent EP2437750. JB256159 - Sequence 78 from Patent EP2327710. JB387960 - Sequence 1 from Patent WO2012041959. JB616197 - Sequence 27 from Patent WO2013107459. JB620043 - Sequence 23 from Patent WO2013063544. JB620195 - Sequence 175 from Patent WO2013063544. JB622365 - Sequence 356 from Patent EP2586454. JB622863 - Sequence 356 from Patent EP2586455. JB624150 - Sequence 34 from Patent EP2610347. JB624270 - Sequence 90 from Patent EP2610342. JB778787 - Sequence 166 from Patent WO2013078283. JC001926 - Sequence 356 from Patent EP2591794. JC032749 - Sequence 21 from Patent WO2013160474. JC037524 - Sequence 52 from Patent EP2643479. JC171729 - Sequence 101 from Patent WO2013150303. JC244446 - Sequence 66 from Patent WO2012020308. JC244894 - Sequence 522 from Patent WO2012020308. JC270183 - Sequence 574 from Patent WO2012020307. JC512898 - Sequence 3151 from Patent WO2014113089. JC572032 - Sequence 46 from Patent EP2759595. JC572540 - Sequence 101 from Patent WO2014125276. JC582228 - Sequence 101 from Patent WO2014125277. JE867391 - Sequence 198 from Patent WO2015128671. JE953924 - Sequence 101 from Patent WO2015052526. JE955677 - Sequence 101 from Patent WO2015052527. JE978774 - Sequence 219 from Patent EP2865765. LF132481 - JP 2016506923-A/46: Composition comprising an encapsulated antagomir. LF137429 - JP 2016507550-A/101: Method of Producing Microparticles. LF161760 - JP 2016513950-A/1826: Oligomers with improved off-target profile. LF162394 - JP 2016513095-A/101: Stem Cell Microparticles and miRNA. LF636310 - JP 2016519076-A/84: COMBINATION CANCER TREATMENTS UTILIZING MICRORNA AND EGFR-TKI INHIBITORS. LF953146 - JP 2016534103-A/101: Stem Cell Microparticles and miRNA. LG005491 - KR 1020150004822-A/101: STEM CELL MICROPARTICLES. LG046505 - KR 1020150023687-A/50: Oligonucleotide-Based Inhibitors Comprising Locked Nucleic Acid Motif. LG053187 - KR 1020150059168-A/101: STEM CELL MICROPARTICLES. LG134467 - KR 1020150131312-A/84: COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS. LG162345 - KR 1020160018451-A/46: Composition comprising an encapsulated antagomir. LG240426 - KR 1020160035087-A/101: STEM CELL MICROPARTICLES AND MIRNA. LP010710 - Sequence 15 from Patent EP2977463. LP726723 - Sequence 417 from Patent EP2883966. LP818993 - Sequence 417 from Patent EP3296406. LP884025 - Sequence 3 from Patent WO2017167934. LP884035 - Sequence 13 from Patent WO2017167934. LP938935 - Sequence 417 from Patent EP3184651. LP951818 - Sequence 324 from Patent WO2017157650. LP973065 - Sequence 11 from Patent EP3216869. LQ070486 - Sequence 810 from Patent EP2964234. LQ417665 - Sequence 1 from Patent WO2016125163. LQ754445 - Sequence 23 from Patent EP3329005. LQ840940 - Sequence 50 from Patent EP3354734. LV470511 - JP 2016534036-A/101: Stem Cell Microparticles and miRNA. LV539153 - JP 2016539127-A/154: C/EBP ALPHA COMPOSITIONS AND METHODS OF USE. LV746125 - JP 2015521626-A/50: OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF. LX154550 - JP 2017509333-A/198: Biomarkers for Endometriosis. LX270640 - JP 2016056210-A/574: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS. LY298555 - KR 1020160079824-A/154: C/EBP ALPHA SHORT ACTIVATING RNA COMPOSITIONS AND METHODS OF USE. LY405218 - KR 1020160117535-A/523: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. LY416904 - KR 1020160145093-A/10: USE OF MICRO-RIBONUCLEIC ACID(MIRNA) TO DIAGNOSE TRANSPLANT REJECTION AND TOLERANCE OF IMMUNOSUPPRESSION THERAPY. LY504787 - KR 1020170035932-A/176: MICRORNA BIOMARKER FOR THE DIAGNOSIS OF GASTRIC CANCER. LZ233914 - JP 2017184756-A/306: Oligonucleotides for modulating target RNA activity. LZ243068 - JP 2017525350-A/176: MICRORNA BIOMARKER FOR THE DIAGNOSIS OF GASTRIC CANCER. LZ986415 - JP 2017225396-A/17: Complex and use thereof. LZ991536 - WO 2017221875-A/17: COMPLEX AND USE THEREOF. MA260457 - JP 2017505623-A/523: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. MS816745 - Sequence 94 from Patent WO2017085287. MS833385 - Sequence 90 from Patent EP3112464. MS834292 - Sequence 438 from Patent EP3112479. MS944920 - Sequence 176 from Patent EP3177739. MP174434 - Sequence 19 from Patent WO2019058253. MP129503 - Sequence 403 from Patent EP3470073. MP162124 - Sequence 101 from Patent WO2019069093. MP162426 - Sequence 403 from Patent WO2019069093. MP129201 - Sequence 101 from Patent EP3470073. MA643986 - JP 2017113010-A/1910: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA731870 - JP 2017140048-A/740: TERMINALLY MODIFIED RNA. MA643987 - JP 2017113010-A/1911: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA730787 - JP 2017125065-A/574: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS. MA731871 - JP 2017140048-A/741: TERMINALLY MODIFIED RNA. MA783867 - WO 2018181877-A/8: Anti-cancer agent using miRNA. MA784178 - WO 2018194089-A/1: GENE-MODIFIED COXSACKIEVIRUS AND PHARMACEUTICAL COMPOSITION. LQ938809 - Sequence 3 from Patent EP2774990. LQ938810 - Sequence 4 from Patent EP2774990. LQ932799 - Sequence 23 from Patent EP2802207. MA405579 - WO 2018155427-A/353: A probe with reduced false positive binding, a method to desing the probe, and the use thereof. MA419982 - JP 2018518169-A/33: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420006 - JP 2018518169-A/57: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420023 - JP 2018518169-A/74: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420059 - JP 2018518169-A/110: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420090 - JP 2018518169-A/141: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420107 - JP 2018518169-A/158: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420132 - JP 2018518169-A/183: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420163 - JP 2018518169-A/214: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA420183 - JP 2018518169-A/234: NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS. MA625402 - JP 2018138044-A/8: METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS. MA625400 - JP 2018138044-A/6: METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS. MP065922 - Sequence 36 from Patent WO2018228875. MP065923 - Sequence 37 from Patent WO2018228875. MP075720 - Sequence 59 from Patent WO2019002265. MP070429 - Sequence 26 from Patent WO2018231851. MP075662 - Sequence 1 from Patent WO2019002265. MP075676 - Sequence 15 from Patent WO2019002265. MP075721 - Sequence 60 from Patent WO2019002265. MA801039 - JP 2018183181-A/1910: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA801040 - JP 2018183181-A/1911: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA820033 - JP 2018534542-A/3: METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS. MA886369 - WO 2019049612-A/9: An antitumor agent, food and beverage for prevention of cancer and an agent for increasing expression of tumor-suppressive microRNA. MA896107 - JP 2017217007-A/50: OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF. MP280637 - Sequence 57 from Patent WO2019111197. MP264454 - Sequence 42 from Patent EP3502269. MP280638 - Sequence 58 from Patent WO2019111197. MP283550 - Sequence 57 from Patent WO2019111198. MP272074 - Sequence 22 from Patent WO2019157381. MP283551 - Sequence 58 from Patent WO2019111198. LY628288 - KR 1020180132092-A/3: NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS. LY628298 - KR 1020180132092-A/13: NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS. LY581972 - KR 1020180120565-A/1: Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors. MB119615 - WO 2019117257-A/137: Method of aiding detection of breast cancer. MB407129 - WO 2019159884-A/619: Kit, device, and method for detection of dementia. MB407562 - WO 2019159884-A/1052: Kit, device, and method for detection of dementia. MB406733 - WO 2019159884-A/223: Kit, device, and method for detection of dementia. MB460604 - JP 2018523492-A/39: METHODS FOR DETECTING AND TREATING LOW-VIRULENCE INFECTIONS. MB453666 - JP 2018509178-A/232: Methods for Highly Parallel and Accurate Measurement of Nucleic Acids. MB457995 - JP 2018522558-A/23: MICRORNA BIOMARKERS FOR TRAUMATIC BRAIN INJURY AND METHODS OF USE THEREOF. MP330039 - Sequence 4 from Patent WO2019180153. MP335229 - Sequence 11 from Patent WO2019185823. MP337302 - Sequence 11 from Patent EP3546597. MP330036 - Sequence 1 from Patent WO2019180153. MP336917 - Sequence 1 from Patent WO2019185864.
| |
|
|
Other Names for This Gene
|
|
Alternate Gene Symbols: NR_029610, uc318ssm.1 UCSC ID: ENST00000385130.1 RefSeq Accession: NR_029610.1
| |
|
|
Gene Model Information
|
|
Click here
for a detailed description of the fields of the table above.
| |
|
|
Methods, Credits, and Use Restrictions
|
|
Click here
for details on how this gene model was made and data restrictions if any.
| |
|
|
|